Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease.

Nephrology Dialysis Transplantation, gfx350, https://doi.org/10.1093/ndt/gfx350

In the above article, the n numbers for the least squares mean values (LSM) reported below figure 2A were incorrect. The numbers for Week 102 were repeated under the graph rather than displaying the true LSM values, which were 62 for placebo, 55 for dapagliflozin 5 mg and 85 for dapagliflozin 10 mg. The authors apologise for the error which has been corrected.